TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21928256

Group type: EXPERIMENTAL
Intervention: 5.2-mm trapezoidal corneal incision (TCI)
Number of subjects: 69

Group type: COMPARATOR
Intervention: 5.2-mm scleral tunnel incision (STI)
Number of subjects: 69
Study: 20118170

Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering medication
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Knowledge regarding optimal LDL levels
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Patient engagement in treatment decisions
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Awareness of medication requests
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Patient inquiries about medication
Number of subjects: 355
Study: 18567675

Group type: EXPERIMENTAL
Intervention: Intra-articular dexmedetomidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (i.v. and intra-articular saline)
Number of subjects: 60
Study: 16529667

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg every 4 hours (to a maximum of four doses)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Intra-amniotic PGF2alpha 40 mg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 117
Study: 10480263

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times per week for up to 16 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 19
Study: 8583605

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 32

Group type: COMPARATOR
Intervention: 3-drug mixture (17.64 mg/ml papaverine, 0.58 mg/ml phentolamine, 5.8 micrograms/ml prostaglandin E1)
Number of subjects: 32
Study: 1918458

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient 0.05% cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient 0.01% cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tretinoin emollient 0.001% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle therapy
Number of subjects: 0
Study: 31895867

Group type: EXPERIMENTAL
Intervention: Active Storage Machine (ASM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional Organ Culture (OC)
Number of subjects: 24
Study: 31326225

Group type: EXPERIMENTAL
Intervention: Hydrus microstent implantation after cataract surgery
Number of subjects: 331

Group type: COMPARATOR
Intervention: Phacoemulsification only
Number of subjects: 331
Study: 26946148

Group type: EXPERIMENTAL
Intervention: Cumulative duration of triple-low state (low MAP <65 mmHg, low BIS <45, low Ce <1.5 μg ml-1 of propofol anesthesia)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Cumulative duration of triple-low state
Number of subjects: 489
Study: 26793128

Group type: EXPERIMENTAL
Intervention: Cognitive enhancement therapy (CET)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study: 23064511

Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CT anterior guidance
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CT posterior guidance
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 125
Study: 21629190

Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14 capsules)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 29
Study: 19443419

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (2 mg kg(‐1) h(‐1) during surgery and 1 mg kg(‐1) min(‐1) for the first 24 postoperative hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (saline 0.9%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 40
Study: 16462564

Group type: EXPERIMENTAL
Intervention: Closed reduction and casting (n = 59)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Closed reduction and external fixation (n = 54)
Number of subjects: 113
Study: 14742378

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.08 microg.kg(‐1).min(‐1), 40 min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gabapentin (600 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11316241

Group type: EXPERIMENTAL
Intervention: 200 mg i.v. Fe as Fe sucrose (Venofer, Vifor Int.) once per week for 5 doses + 2,000 IU EPO (Eprex, Cilag‐Janssen), subcutaneously for 5 doses
Number of subjects: 90

Group type: COMPARATOR
Intervention: i.v. Fe alone (same dose as Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: i.v. Fe alone during follow-up
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: i.v. Fe + EPO during follow-up
Number of subjects: 90
Study: 9396542

Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (2 to 8 sessions)
Number of subjects: 31
Study: 7895957

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (experimental group, n = 16)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional therapy (control group, n = 5)
Number of subjects: 21
Study: 3605568

Group type: EXPERIMENTAL
Intervention: Enflurane with N2O and O2
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Isoflurane with N2O and O2
Number of subjects: 76
Study: 30948068

Group type: EXPERIMENTAL
Intervention: 5% GA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10% GA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17% GA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 10% citric acid (CA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GA and CA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 100
Study: 27821210

Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg bid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg bid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg once daily
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Asenapine (both doses)
Number of subjects: 311
Study: 25842559

Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined anterior and posterior approach
Number of subjects: 66
Study: 22656044

Group type: EXPERIMENTAL
Intervention: Guided treatment (clopidogrel non-responders received repeated loading doses of clopidogrel or prasugrel)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Non-guided treatment (clopidogrel non-responders did not undergo any change in treatment)
Number of subjects: 798

Group type: EXPERIMENTAL
Intervention: Guided treatment
Number of subjects: 798

Group type: COMPARATOR
Intervention: Non-guided treatment
Number of subjects: 798
Study: 21443324

Group type: EXPERIMENTAL
Intervention: Social PM tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social PM task
Number of subjects: 0
Study: 19450044

Group type: EXPERIMENTAL
Intervention: Trait positive affect (PA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No Stress (reading task)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stress (Trier Social Stress Test)
Number of subjects: 60
Study: 17044935

Group type: EXPERIMENTAL
Intervention: Worksite environmental intervention
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 515
Study: 15249618

Group type: EXPERIMENTAL
Intervention: Current hormone users
Number of subjects: 13807

Group type: EXPERIMENTAL
Intervention: Long-term users of estrogen alone or combined with progestin
Number of subjects: 13807

Group type: EXPERIMENTAL
Intervention: Women initiating hormones at older ages
Number of subjects: 13807

Group type: COMPARATOR
Intervention: Never users
Number of subjects: 13807
Study: 10789747

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 40 mg containing 20 mg chlorpheniramine maleate (intramuscular)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorpheniramine maleate (20 mg, intramuscular)
Number of subjects: 60
Study: 9146776

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8377241

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 893

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 893
Study: 3099028

Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) otic solution
Number of subjects: 587
Study: 30260372

Group type: EXPERIMENTAL
Intervention: iPad administration of the Flanker Inhibitory Control and Attention Test
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: iPad administration of the Pattern Comparison Processing Speed Test
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: iPad administration of the Dimensional Change Card Sort Test
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: iPad administration of the List Sorting Working Memory Test
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Preference for iPad administration
Number of subjects: 49
Study: 28601833

Group type: EXPERIMENTAL
Intervention: De-escalation from an empirical beta-lactam with antipseudomonal activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted narrow-spectrum antimicrobial
Number of subjects: 0
Study: 25622970

Group type: EXPERIMENTAL
Intervention: Health literacy-informed, electronic health record-based strategy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 600
Study: 23975325

Group type: EXPERIMENTAL
Intervention: Aerobic training with metformin
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Aerobic training without metformin
Number of subjects: 251

Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 251

Group type: COMPARATOR
Intervention: Combined aerobic and resistance training
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (waiting-list)
Number of subjects: 251
Study: 21767015

Group type: EXPERIMENTAL
Intervention: Brief family intervention (BFI)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 256
Study: 19464546

Group type: EXPERIMENTAL
Intervention: Conjugate Haemophilus influenzae type b vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Native Indian infants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malnourished infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated native Indian infants
Number of subjects: 0
Study: 16451145

Group type: EXPERIMENTAL
Intervention: Desflurane/fentanyl
Number of subjects: 49

Group type: COMPARATOR
Intervention: TIVA (propofol/remifentanil)
Number of subjects: 49
Study: 15010697

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg plus titrated dose of yohimbine (F/Y)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg plus placebo (F/P)
Number of subjects: 50
Study: 11379254

Group type: EXPERIMENTAL
Intervention: Mensendieck exercise programme (20 group sessions over 13 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no prophylactic therapy, free to receive treatment or exercises)
Number of subjects: 77
Study: 9715671

Group type: EXPERIMENTAL
Intervention: Duration-production task during cognitive tasks (Stroop or card-sorting)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration-estimation task during cognitive tasks (Stroop or card-sorting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group performing non-temporal tasks without timing tasks
Number of subjects: 0
Study: 8026057

Group type: EXPERIMENTAL
Intervention: Streptokinase (n = 115)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Anistreplase (n = 129)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Perfusion grade 2
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Perfusion grade 3
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Left anterior descending coronary artery occlusion
Number of subjects: 244

Group type: COMPARATOR
Intervention: Right and left circumflex coronary artery occlusion
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Anterior AMI
Number of subjects: 244

Group type: COMPARATOR
Intervention: Inferior/lateral AMI
Number of subjects: 244
Study: 12282925

Group type: EXPERIMENTAL
Intervention: gemeprost
Number of subjects: 66

Group type: COMPARATOR
Intervention: Lamicel
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dilapan
Number of subjects: 66
Study: 1207633

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 2 mg three times daily for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Before treatment
Number of subjects: 40
Study: 30514245

Group type: EXPERIMENTAL
Intervention: The Growth Factory (online mindset intervention)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 120
Study: 28786978

Group type: EXPERIMENTAL
Intervention: Estradiol (E2) treatment after 3 months of GnRH agonist (Lupron) ovarian suppression for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Progesterone (P4) treatment after 3 months of GnRH agonist (Lupron) ovarian suppression for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lupron plus E2 treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lupron plus P4 treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E2 addback compared with Lupron in women with PMDD
Number of subjects: 30
Study: 26220254

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both Sirolimus and Cyclosporine A
Number of subjects: 62
Study: 23769551

Group type: EXPERIMENTAL
Intervention: Benidipine (n = 101)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Losartan (n = 99)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Benidipine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Benidipine and Losartan
Number of subjects: 200
Study: 21858460

Group type: EXPERIMENTAL
Intervention: Insulating houses
Number of subjects: 1759

Group type: EXPERIMENTAL
Intervention: Installing more effective heating in insulated houses
Number of subjects: 1759
Study: 18931211

Group type: EXPERIMENTAL
Intervention: 0.1 mL/kg of 1% lidocaine with 1:200,000 epinephrine (0.5 mug/kg of epinephrine) IV
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: HR and SBP criteria
Number of subjects: 80
Study: 16549968

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir
Number of subjects: 0
Study: 12670779

Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Formoterol pre-treatment + formoterol 18 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Placebo pre-treatment + formoterol 18 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo pre-treatment + placebo
Number of subjects: 16
Study: 11105736

Group type: EXPERIMENTAL
Intervention: Immediate olanzapine initiation (olanzapine, 10 mg q.d. for 3 weeks)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Stepwise initiation (a sequence of 1 week each on placebo; olanzapine, 5 mg q.d.; and olanzapine, 10 mg q.d.)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of prior antipsychotic drug
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Gradual discontinuation of prior antipsychotic drug
Number of subjects: 209
Study: 9167809

Group type: EXPERIMENTAL
Intervention: Iontophoresis of 0.4% dexamethasone plus traditional modalities
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo iontophoresis plus traditional modalities
Number of subjects: 40
Study: 8249574

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3856667

Group type: EXPERIMENTAL
Intervention: Occlusal splint adjusted to mean vertical dimension of 4.25 mm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Occlusal splint adjusted to mean vertical dimension of 8.25 mm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Occlusal splint adjusted to 1 mm from occlusal vertical dimension (Control group)
Number of subjects: 60
Study: 31439408

Group type: EXPERIMENTAL
Intervention: Mydrane® (0.02% tropicamide, 0.31% phenylephrine, 1% lidocaine)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Mydriasert® (0.28mg tropicamide insert and 5.4mg phenylephrine)
Number of subjects: 82
Study: 29501215

Group type: EXPERIMENTAL
Intervention: Video version enriched with text hints denoting the SPIKES steps
Number of subjects: 67

Group type: COMPARATOR
Intervention: Video version
Number of subjects: 67

Group type: COMPARATOR
Intervention: Text version
Number of subjects: 67
Study: 27088471

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) cycling training for 15 days (30 minutes daily for 5 days a week)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional resistance and aerobic training for 6 weeks
Number of subjects: 8
Study: 24379328

Group type: EXPERIMENTAL
Intervention: MARC Patient Simulator instruction for Group 1
Number of subjects: 2

Group type: COMPARATOR
Intervention: MARC Patient Simulator instruction for Group 2
Number of subjects: 2

Group type: COMPARATOR
Intervention: MARC Patient Simulator for Group 3 (fourth-year DS) and Group 4 (dentists)
Number of subjects: 2
Study: 23921278

Group type: EXPERIMENTAL
Intervention: Preincision intra-aortic balloon pump
Number of subjects: 110

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 110
Study: 20590718

Group type: EXPERIMENTAL
Intervention: Letters and digits
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symbols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: W-shaped serial position functions for letters and digits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deficit size for letters and digits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symbol-sound mapping
Number of subjects: 0
Study: 18377650

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 16899362

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily for the first 7 days, increased by 25 mg each week up to 150 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily for 21 days followed by a 7-day rest period, repeated for 3 cycles
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg daily continuously
Number of subjects: 55
Study: 14639082

Group type: EXPERIMENTAL
Intervention: 6-week peer-led program
Number of subjects: 327

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 327
Study: 11171466

Group type: EXPERIMENTAL
Intervention: Experimental group (listened to words 'banana', 'melon', 'white', 'black')
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (listened to environmental operating room noise)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Experimental group (younger patients)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Experimental group (patients with greater anxiety)
Number of subjects: 48
Study: 8619941

Group type: EXPERIMENTAL
Intervention: Sustained-release metoclopramide (60 mg every 12 h, total of 300 mg in 2.5 days) plus methylprednisolone (M)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo plus methylprednisolone (M)
Number of subjects: 50
Study: 1471511

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 3510823

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg thrice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg thrice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 41
Study: 29486097

Group type: EXPERIMENTAL
Intervention: STH+G advertisements
Number of subjects: 3718

Group type: EXPERIMENTAL
Intervention: LTH+G advertisements
Number of subjects: 3718

Group type: EXPERIMENTAL
Intervention: STH advertisements
Number of subjects: 3718

Group type: EXPERIMENTAL
Intervention: LTH advertisements
Number of subjects: 3718

Group type: COMPARATOR
Intervention: ALC control
Number of subjects: 3718

Group type: COMPARATOR
Intervention: NON-ALC control
Number of subjects: 3718
Study: 27558161

Group type: EXPERIMENTAL
Intervention: Long-lasting microbial larvicide (FourStar controlled release larvicide, 6% by weight Bacillus thuringiensis israelensis and 1% Bacillus sphaerius) applied in treatment clusters for three rounds at 4-month intervals.
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention (control) in the control clusters.
Number of subjects: 28
Study: 24902814

Group type: EXPERIMENTAL
Intervention: Single-port TEP hernia repair
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional 3-port TEP hernia repair
Number of subjects: 50
Study: 23327091

Group type: EXPERIMENTAL
Intervention: Oral care group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 19965693

Group type: EXPERIMENTAL
Intervention: Normal D-dimer (D-d) at 1 month after anticoagulation suspension
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: D-d abnormal at the third month and remained abnormal afterward
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: D-d remained normal at the third month and afterward
Number of subjects: 355
Study: 17445878

Group type: EXPERIMENTAL
Intervention: Right hemisphere (RH) processing of unfamiliar two-word novel metaphoric expressions (signal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hemisphere (RH) processing of literal expressions (signal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrelated word pairs (noise)
Number of subjects: 0